Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Burning Rock Biotech Limited's Business Segments
Burning Rock Biotech Limited's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of 2025 ((Dec 31 2025))
Reportable Segments
3
Largest Segment
Inhospital Business
Total Revenue
$ 77
Regions Reported
1
Annual Results
Revenue Share by Reportable Segment - FY2025
- Inhospital Business0%
- Central Laboratory Business0%
- Pharma Research and Development Services0%
Revenue by Reportable Segment - FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Inhospital Business | $ 224 | - |
| Central Laboratory Business | $ 160 | - |
| Pharma Research and Development Services | $ 156 | - |
Revenue Share by Region - FY2025
- Geographic Distribution Foreign0%
Revenue by Geographic Region - FY2025
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Geographic Distribution Foreign | $ 439 | - |
Revenue by Product & Service Category - FY2025
- Service0%
- Product0%
Revenue by Product & Service Category - FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 316 | - |
| Product | $ 223 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Burning Rock Biotech Limited
Burning Rock Biotech Limited is a leading company in the field of precision oncology in China. Founded in 2014, the company specializes in developing and commercializing Next-Generation Sequencing (NGS) assays for the diagnosis and treatment of cancers.
Burning Rock Biotech's primary focus is on the detection and analysis of genetic mutations in tumor tissue samples. By using advanced NGS technology, the company aims to identify specific genetic alterations that can guide oncologists in choosing the most effective treatment options for cancer patients.
The company offers a wide range of NGS-based clinical testing services, including solid tumor-based tests, liquid biopsy tests, and companion diagnostic tests. These tests enable the detection of various cancer-related genetic alterations, such as gene mutations, copy number variations, rearrangements, and microsatellite instability, among others.
Burning Rock Biotech has developed several proprietary testing platforms and panels, such as the GenID®, DiseaseID®, and PlasmaSELECT™, which help in accurate and comprehensive profiling of tumors and assessment of treatment response. These platforms integrate NGS technology with advanced bioinformatics analysis, allowing for efficient and reliable detection of cancer-related mutations and alterations.
Apart from diagnostic testing services, Burning Rock Biotech also collaborates with pharmaceutical companies and research institutions to develop companion diagnostics. These diagnostics are essential for identifying patients who are likely to respond to specific targeted therapies, thereby improving treatment outcomes and reducing side effects. Additionally, the company also conducts clinical trials to evaluate the safety and efficacy of novel targeted therapies and immunotherapies.
To ensure the highest quality and accuracy in their testing services, Burning Rock Biotech has established a robust quality management system. The company adheres to internationally recognized standards and holds multiple accreditations and certifications, such as the ISO 13485:2016 and the Clinical Laboratory Improvement Amendments (CLIA). This ensures compliance with regulatory requirements for clinical testing and provides confidence to both patients and healthcare providers.
Burning Rock Biotech has a strong and experienced team of scientists, clinicians, and bioinformaticians who work collaboratively to drive innovation in precision oncology. The company emphasizes the importance of interdisciplinary collaboration and actively engages in partnerships with academic and medical institutions around the world.
With a commitment to improving the lives of cancer patients, Burning Rock Biotech is continuously expanding its portfolio of testing services and diagnostic solutions. Through its cutting-edge technology platforms and comprehensive genomic profiling capabilities, the company is making significant contributions to advancing precision oncology and personalized medicine in the fight against cancer.
Burning Rock Biotech's primary focus is on the detection and analysis of genetic mutations in tumor tissue samples. By using advanced NGS technology, the company aims to identify specific genetic alterations that can guide oncologists in choosing the most effective treatment options for cancer patients.
The company offers a wide range of NGS-based clinical testing services, including solid tumor-based tests, liquid biopsy tests, and companion diagnostic tests. These tests enable the detection of various cancer-related genetic alterations, such as gene mutations, copy number variations, rearrangements, and microsatellite instability, among others.
Burning Rock Biotech has developed several proprietary testing platforms and panels, such as the GenID®, DiseaseID®, and PlasmaSELECT™, which help in accurate and comprehensive profiling of tumors and assessment of treatment response. These platforms integrate NGS technology with advanced bioinformatics analysis, allowing for efficient and reliable detection of cancer-related mutations and alterations.
Apart from diagnostic testing services, Burning Rock Biotech also collaborates with pharmaceutical companies and research institutions to develop companion diagnostics. These diagnostics are essential for identifying patients who are likely to respond to specific targeted therapies, thereby improving treatment outcomes and reducing side effects. Additionally, the company also conducts clinical trials to evaluate the safety and efficacy of novel targeted therapies and immunotherapies.
To ensure the highest quality and accuracy in their testing services, Burning Rock Biotech has established a robust quality management system. The company adheres to internationally recognized standards and holds multiple accreditations and certifications, such as the ISO 13485:2016 and the Clinical Laboratory Improvement Amendments (CLIA). This ensures compliance with regulatory requirements for clinical testing and provides confidence to both patients and healthcare providers.
Burning Rock Biotech has a strong and experienced team of scientists, clinicians, and bioinformaticians who work collaboratively to drive innovation in precision oncology. The company emphasizes the importance of interdisciplinary collaboration and actively engages in partnerships with academic and medical institutions around the world.
With a commitment to improving the lives of cancer patients, Burning Rock Biotech is continuously expanding its portfolio of testing services and diagnostic solutions. Through its cutting-edge technology platforms and comprehensive genomic profiling capabilities, the company is making significant contributions to advancing precision oncology and personalized medicine in the fight against cancer.
Burning Rock Biotech Limited is a prominent player in the field of precision medicine, specializing in genomic profiling and advanced diagnostics. The company offers a range of segments and products designed for various applications, particularly in oncology.
Segments
1. Genomic Testing and Diagnostics: This segment focuses on providing comprehensive genomic tests that analyze multiple genes simultaneously. This includes panels for cancer patients, which help in identifying mutations and alterations that could influence treatment decisions.
2. Biopharmaceutical Development: Burning Rock collaborates with pharmaceutical companies to develop companion diagnostics that help identify patients who are most likely to benefit from specific targeted therapies. This segment bridges the gap between drug development and patient treatment.
3. Research Services: The company also provides research services for academic and clinical researchers looking for high-throughput genomic analyses. This includes access to advanced sequencing technologies and bioinformatics analysis.
4. Bioinformatics and Data Management: Burning Rock emphasizes the importance of data interpretation in genomic testing. This segment includes services that leverage machine learning and artificial intelligence for enhanced genomic data analysis and patient outcome prediction.
Products
1. NMPA-Approved Tests
- Onco Panels: These are panels of targeted genes that provide insights into specific types of cancers. The panels cover key genes known to be involved in tumorigenesis and are essential for personalized cancer therapy.
- Liquid Biopsies: Utilizing blood samples, liquid biopsies detect circulating tumor DNA (ctDNA), offering a non-invasive alternative to traditional tissue biopsies for cancer detection and monitoring.
Technology Platforms
- NGS Technology: Burning Rock employs advanced Next-Generation Sequencing (NGS) technologies, which allow for high-throughput sequencing of DNA and RNA to identify genetic mutations and alterations.
- Bioinformatics Platforms: The company utilizes sophisticated software to manage and analyze complex genomic data, providing actionable insights for healthcare providers and researchers.
Clinical Applications
- Tumor Mutational Burden (TMB) Testing: This product measures the number of mutations within a tumor, which can provide insights into the tumors behavior and potential response to immunotherapy.
- MSI Testing: Microsatellite instability (MSI) testing is crucial for identifying patients who may be eligible for immunotherapy treatment, specifically in certain types of cancers.
Services
1. Gene Sequencing Services: Burning Rock offers comprehensive gene sequencing services that enable healthcare providers to gain insights into the genetic basis of diseases, not only limited to cancer but also offering insights into hereditary conditions.
2. Consultation Services: The company provides expert consultation services to assist healthcare professionals in interpreting genomic data and integrating it into clinical decision-making processes.
3. Educational Programs: To promote awareness and understanding of genomic testing, Burning Rock conducts educational programs and workshops aimed at healthcare professionals, researchers, and patients.
4. Patient Support Programs: Understanding the emotional and psychological impacts of cancer, the company also offers support services to patients, providing resources for navigating the complexities of cancer treatment based on genomic insights.
Conclusion
Burning Rock Biotech Limited operates at the intersection of technology and medicine, utilizing genomic information to revolutionize cancer diagnostics and treatment. Through its diverse segments, products, and services, the company plays a critical role in advancing personalized medicine, contributing to better patient outcomes and fostering innovation in the healthcare landscape.
Segments
1. Genomic Testing and Diagnostics: This segment focuses on providing comprehensive genomic tests that analyze multiple genes simultaneously. This includes panels for cancer patients, which help in identifying mutations and alterations that could influence treatment decisions.
2. Biopharmaceutical Development: Burning Rock collaborates with pharmaceutical companies to develop companion diagnostics that help identify patients who are most likely to benefit from specific targeted therapies. This segment bridges the gap between drug development and patient treatment.
3. Research Services: The company also provides research services for academic and clinical researchers looking for high-throughput genomic analyses. This includes access to advanced sequencing technologies and bioinformatics analysis.
4. Bioinformatics and Data Management: Burning Rock emphasizes the importance of data interpretation in genomic testing. This segment includes services that leverage machine learning and artificial intelligence for enhanced genomic data analysis and patient outcome prediction.
Products
1. NMPA-Approved Tests
- Onco Panels: These are panels of targeted genes that provide insights into specific types of cancers. The panels cover key genes known to be involved in tumorigenesis and are essential for personalized cancer therapy.
- Liquid Biopsies: Utilizing blood samples, liquid biopsies detect circulating tumor DNA (ctDNA), offering a non-invasive alternative to traditional tissue biopsies for cancer detection and monitoring.
Technology Platforms
- NGS Technology: Burning Rock employs advanced Next-Generation Sequencing (NGS) technologies, which allow for high-throughput sequencing of DNA and RNA to identify genetic mutations and alterations.
- Bioinformatics Platforms: The company utilizes sophisticated software to manage and analyze complex genomic data, providing actionable insights for healthcare providers and researchers.
Clinical Applications
- Tumor Mutational Burden (TMB) Testing: This product measures the number of mutations within a tumor, which can provide insights into the tumors behavior and potential response to immunotherapy.
- MSI Testing: Microsatellite instability (MSI) testing is crucial for identifying patients who may be eligible for immunotherapy treatment, specifically in certain types of cancers.
Services
1. Gene Sequencing Services: Burning Rock offers comprehensive gene sequencing services that enable healthcare providers to gain insights into the genetic basis of diseases, not only limited to cancer but also offering insights into hereditary conditions.
2. Consultation Services: The company provides expert consultation services to assist healthcare professionals in interpreting genomic data and integrating it into clinical decision-making processes.
3. Educational Programs: To promote awareness and understanding of genomic testing, Burning Rock conducts educational programs and workshops aimed at healthcare professionals, researchers, and patients.
4. Patient Support Programs: Understanding the emotional and psychological impacts of cancer, the company also offers support services to patients, providing resources for navigating the complexities of cancer treatment based on genomic insights.
Conclusion
Burning Rock Biotech Limited operates at the intersection of technology and medicine, utilizing genomic information to revolutionize cancer diagnostics and treatment. Through its diverse segments, products, and services, the company plays a critical role in advancing personalized medicine, contributing to better patient outcomes and fostering innovation in the healthcare landscape.